Cancer Biology

Cancer Biology

eLife publishes research into cancer spanning from oncogenes and tumor suppressors to metastasis and anticancer treatments. Learn more about what we publish and sign up for the latest research.
Illustration by Davide Bonazzi

Latest articles

    1. Cancer Biology
    2. Cell Biology

    MAPK activity dynamics regulate non-cell autonomous effects of oncogene expression

    Timothy J Aikin et al.
    The temporal patterns of MAPK activity differentially regulate cell autonomous and non-cell autonomous effects of oncogene expression.
    1. Cancer Biology
    2. Cell Biology

    Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling

    Yingqi Liu et al.
    PRMT7-mediated SHANK2 methylation regulates breast cancer metastasis by activating endosomal FAK signals, and may provide potential clues for tumour metastasis treatment strategies.
    1. Cancer Biology
    2. Cell Biology

    PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response

    Chiho Kim et al.
    Identification of PARP1 trapping as the major contributor of PARP1 inhibitor-induced innate immune response.
    1. Cancer Biology
    2. Physics of Living Systems

    Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy

    Xin Cui et al.
    A biomimetic and patient-specific Glioblastoma-on-a-Chip microphysiological system provides an avenue for personalized screening of PD-1 immunotherapy and novel combinational therapies that maximize therapeutic outcomes in Glioblastoma patients.
    1. Cancer Biology

    Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer

    Patricia L Theard et al.
    Combined EGFR and SOS1 inhibition synergize to inhibit NSCLC spheroid growth.
    1. Cancer Biology
    2. Immunology and Inflammation

    A perspective on HPK1 as a novel immuno-oncology drug target

    Sansana Sawasdikosol, Steven Burakoff
    HPK1 is an important immuno-oncology drug target that may induce superior anti-tumor immunity through the multiple roles HPK1 may play at multiple steps of the cancer immunity cycle.

Senior editors

  1. Utpal Banerjee
    University of California, Los Angeles, United States
  2. Erica Golemis
    Fox Chase Cancer Center, United States
  3. Maureen Murphy
    The Wistar Institute, United States
  4. See more editors